Ehsanollah Esfandiari
Marlow, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials.
Journal: Lancet (London, England)
Published: August 08, 2025
Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic Dermatitis.
Journal: Dermatology and therapy
Published: May 20, 2025
Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study.
Journal: Dermatology and therapy
Published: September 30, 2024
Durable improvements in atopic dermatitis in the head and neck and across other anatomic regions with rocatinlimab.
Journal: Archives of dermatological research
Published: August 15, 2024
Correction to: OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.
Journal: American journal of clinical dermatology
Published: February 10, 2024
OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target.
Journal: American journal of clinical dermatology
Published: December 13, 2023
Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews.
Journal: The British journal of dermatology
Published: October 20, 2023
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study.
Journal: Advances in therapy
Published: October 10, 2023
Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis - Authors' reply.
Journal: Lancet (London, England)
Published: February 22, 2023
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study.
Journal: Lancet (London, England)
Published: August 04, 2022
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Journal: Clinical and translational science
Published: June 05, 2020
Last Updated: 09/26/2026